Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
May 17, 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and...